Inhibitory activity of the peptides derived from buffalo prolactin on angiogenesis by Lee, Jaeok et al.
Inhibitory activity of the peptides derived from buffalo prolactin
on angiogenesis
JAEOK LEE1, SYAMANTAK MAJUMDER2, SUVRO CHATTERJEE2 and KAMBADUR MURALIDHAR1,*
1Hormone Research Laboratory, Department of Zoology, University of Delhi, Delhi, India
2AU-KBC Research Centre, MIT Campus, Anna University, Chennai, India
*Corresponding author (Fax, +91-11-2766-6564; Email, kambadur@hotmail.com)
The peptide fragments obtained by cathepsin digestion of purified buffalo prolactin (buPRL) monomer have been
characterized using SDS-PAGE and FPLC with regard to size and pI. Their antiangiogenic activity was tested in
chick embryo chorioallantoic membrane (CAM) assay and the human endothelial cells wound healing assay.
Antiangiogenic activity was observed in cathepsin-cleaved fragments from buPRL. Further, a peptide sequence 45A-
46Q-47G-48K-49G-50F-51I-52T-53M-54A-55L-56N-57S-58C, which matched with human somatostatin (hSST), a
known antiangiogenic factor, was located in the second loop between the first and second α-helices in the three-
dimensional structure of buPRL, obtained by homology modelling. The synthetic peptide matching with SST
sequence was found to exhibit antiangiogenic activity in both in vitro and ex vivo assays. It was also observed that all
the peptides related to buPRL could antagonize the vascular endothelial growth factor (VEGF) and bradykinin (BK)-
dependent production of endothelial nitric oxide (NO), which is a pre-requisite for endothelial tube formation. It is
concluded therefore that an internal sequence in buPRL and peptide fragments derived from cathepsin-digested
buPRL exhibit antiangiogenic activities.
[Lee J, Majumder S, Chatterjee S and Muralidhar K 2011 Inhibitory activity of the peptides derived from buffalo prolactin on angiogenesis.
J. Biosci. 36 XXX–XXX] DOI 10.1007/s12038-011-9073-6
1. Introduction
An isoform of rat pituitary prolactin (PRL) with intact
disulfide bonds but with a nick in the sequence was
discovered in 1980 (Mittra 1980a, b). This form had also
been found in mouse pituitary (Sinha and Gilligan 1984),
human pituitary and plasma (Sinha et al. 1985), and also in
rat serum (Nicoll 1997). The nicked rat pituitary PRL was
separated into an N-terminal 16 kDa fragment (16K) and the
C-terminal 8 kDa fragment (8K) by reduction of the
disulfide bonds (Mittra 1980a). The work of Clapp (1987)
demonstrated that only the rat PRL (rPRL) generated the
16K fragment upon incubation with lactating rat mammary
gland extracts, while ovine and human PRLs were pro-
cessed into a variety of low-molecular-weight forms.
It was observed that 16K had an inhibitory effect on
angiogenesis, both in vitro and ex vivo, in rat (Ferrara et al.
1991) and in human (Clapp et al. 1993), whereas intact PRL
had pro-angiogenic (Struman et al. 1999) and proliferative
action on mammary carcinoma cells (Clevenger et al. 2003).
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Rat 16K inhibited the basal growth of capillary endothelial
cells and also that stimulated by fibroblast growth factor
(FGF), but intact and nicked PRL did not show any
inhibitory activity (Ferrara et al. 1991). Nanomolar amounts
of recombinant human 16K (h16K) inhibited the growth of
bovine brain basal endothelial (BBBE) cells induced by
basic FGF or vascular endothelial growth factor (VEGF)
(Clapp et al. 1993). Human 16K PRL obtained by cleavage
of intact PRL using rat mammary gland extracts also
inhibited basic FGF-stimulated human umbilical vein
endothelial (HUVE) cells proliferation (Clapp et al. 1993).
Further, in the chick embryo choriollantoic membrane
(CAM) assay, both the 16Ks inhibited capillary formation
(Ferrara et al. 1991; Clapp et al. 1993).
While cathepsin D (CD) was used for generating an
antiangiogenic 16K rPRL (Baldocchi et al. 1993; Lkhider et
al. 2004), Khurana et al. (1999a, b) showed that a 16K hPRL
isoform generated from the C-terminal end using thrombin
did not posses the same activity. Later, Piwnica et al.
(2006) investigated multiple N-terminal 16K-like fragments
generated by CD. The N-terminal fragments inhibited
thymidine uptake induced by growth factor and MAPK
activation in bovine umbilical vein endothelial (BUVE) cells.
They also, reported that r16K fragment could be generated by
CD secreted from various mouse tissues like kidney, spleen,
brain, heart and prostate, under acidic conditions (Piwnica et
al. 2004). Our own studies on buPRL did not indicate the
presence of a 16K fragment in the CD digestion mixture.
Moreover, we have reported the occurrence of size isoforms in
pure preparations of buPRL (Panchal and Muralidhar 2008),
and there was no 16K isoform. It was therefore it was of
interest to know weather naturally occurring size isoforms of
buPRL and peptide fragments derived by CD digestion of
buPRL have any antiangiogenic activity. Further, the intact
buPRL monomer did not exhibit any pro- or antiangiogenic
activity (Muralidhar and Lee, unpublished work).
Most studies about the antiangiogenic N-terminal fragment
cleaved by CD, however, have been done only in the case of rat
and human PRLs. Based on these observations (Mittra 1980a;
Ferrara et al. 1991; Clapp et al. 1993; Piwnica et al. 2004), it
was hypothesized that buffalo pituitary PRL can be cleaved
by cathepsin, and the fragment could inhibit angiogenesis via
endothelial interference. However, it was not clear which
sequence in the N-terminal fragment plays a role in the
antiangiogenesis. Here, we demonstrate that buPRL size
isoform produced by CD and an antiangiogenic 14-amino-
acid sequence in the hormone identified by BLAST as
somatostatin (SST) have an inhibitory action on angiogenesis.
2. Materials and methods
Buffalo pituitary glands were obtained from a local
slaughter, Delhi. Hatched eggs were collected from the
Poultry Research Station, Nandanam, Chennai. EAhy926,
the immortal HUVE cell line, was obtained from the Tissue
Culture Facility, UNC Lineberger Comprehensive Cancer
Center, USA.
BK, CD, 4-chloro-1-naphthol, pepstatin A, diaminofluor-
escein (DAF-FM), SST and VEGF were purchased from
Sigma, St. Louis, USA. Sephacryl S-200 beads were from
Pharmacia, USA. Goat anti-rabbit IgG to horseradish
peroxidase (HRP) conjugate were from Bangalore Genei,
India. SST-matching sequence in buPRL was commercially
synthesized by Bioconcept, India. All other reagents were of
analytical grade and locally procured.
2.1 Fractionation procedures
2.1.1 Purification of buffalo PRL monomer: Freshly frozen
buffalo pituitary glands were homogenized in 0.15 M
(NH4)2SO4, 1 mM PMSF with a blender. The homogenate
was stirred, adjusted to pH 4.0, allowed to stand for 1 h and
centrifuged at 2000g for 30 min (Papkoff et al. 1965). The
acid pellet was extracted in 0.25 M (NH4)2SO4 (set to pH
5.5) and then followed the next step mentioned in Panchal
and Muralidhar’s procedure (Panchal and Muralidhar 2008).
The precipitation of (AP)P-I 70 was repeated twice as per
published procedure (Panchal and Muralidhar 2008). The
final pellets, (AP)P-III 70 and (AP)P-I 90–70, were
dissolved in 100 mM NH4HCO3, and stored lyophilized.
2.1.2 Sephacryl S-200 gel filtration: The final pellets
dissolved in 100 mM NH4HCO3 were loaded onto separate
column (4.52 cm × 92 cm) of Sephacryl S-200 resin
equilibrated with 100 mM NH4HCO3. The same volume
(5.7 mL) of fractions were collected at a flow rate of
33 mL/h and monitored for absorbance at 280 nm. Peak
aliquots were pooled and lyophilized and then stored at
−20°C.
2.2 Analytical techniques
2.2.1 Protein estimation: Lowry’s method (Lowry et al.
1951) and Bradford’s method (Bradford 1976) were
performed with few modifications to estimate protein
samples.
2.2.2 SDS-PAGE and immunoblot analysis: Protein samples
were separated by 15% SDS-PAGE under reducing or non-
reducing conditions (Laemmli 1970). Gels were either
stained with 0.12% Coomassie blue G-250 (Candiano et al.
2004), or protein transferred to nitrocellulose membrane for
immunoblot analysis (Towbin et al. 1979) with buPRL
antiserum (1:1000). Antigen–antibody complexes were
detected by anti-rabbit immunoglobulin conjugated to HRP
using the substrate, 4-chloro-1-naphthol.
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2.2.3 Dot blot analysis: Two to ten microliter of the
unbound fraction from the fast-performance liquid chroma-
tography (FPLC) was placed on a nitrocellulose membrane
for dot blot analysis with buPRL a/s (1:1000). Antigen–
antibody complexes were detected by the same method as
with immunoblot analysis.
2.3 Enzyme digestion and peptide separation
2.3.1 Proteolysis with CD: Proteolysis of intact buPRL was
performed using Baldocchi’s method (Baldocchi et al.
1993). The reaction was terminated by de-salting with 1K
cut-off centrifugal device (Pall Science, USA) and the
mixture lyophilized.
2.3.2 Separation of the peptides: Elution peptides: The
peptides separated by SDS-PAGE were eluted with the
protocol of Harrington (Harrington 1990).
2.3.3 Separation of the peptides: Fast-performance liquid
chromatography: Buffalo PRL peptide mixture obtained by
CD was separated by anion-exchange chromatography on
an UNO Q1 column (7 mm × 35 mm, 1.3 mL; Bio-Rad,
USA). Five-hundred micrograms of the mixture was
dissolved with 1 mL of the equilibrium buffer (pH 8.0),
and injected after filtering. All buffers were 20 mM Tris (pH
8.0) with a linear gradient 0%–100% of 1 M NaCl in 60 min
with a flow rate of 1 mL/min. The column was used as the
stationary phase (Vogt and Freitag 1998).
2.4 In silico study
2.4.1 Prediction of tertiary structure of proteins: The protein
sequences were downloaded from NCBI (http://www.ncbi.nlm.
nih.gov/RefSeq/). The tertiary structures of protein and peptide
were built with using SWISS-MODEL (Schwede et al. 2003)
and Bhageerath (http://www.scfbio-iitd.res.in/bhageerath), re-
spectively. The tertiary structure analysis and display were
done with ‘Swiss-PdbViewer DeepView v4.0’ (Guex and
Peitsch 1997) of The Swiss Institute of Bioinformatics.
2.4.2 Sequence alignment: Protein sequence alignment was
done with ‘protein tools’ of Biology WorkBench 3.2 (http://
seqtool.sdsc.edu/CGI/BW.cgi).
2.4.3 Biochemical characterization: Physico-chemical
parameters of proteins and peptides were determined using
‘Protparam (ExPASy Proteomics tools [Gasteriger et al. 2005]).
2.5 Antiangiogenic activity analysis
2.5.1 Cell culture: EAhy926 (Edgell et al. 1983), was
maintained in DMEM, supplemented with 10% fetal bovine
serum, penicillin (100 U/mL), and streptomycin (50 pg/mL),
at 37°C/5% CO2 (Astec, Japan).
2.5.2 Wound healing cell migration assay: Cell migration
was observed using the wound healing method (Staton et al.
2004). After 12–16 h of seeding when EAhy926 cells were
confluent, a cross linear wound was created by scratching the
monolayer with a 1-mm-wide sterile plastic scraper. The cells
were treated with protein or peptide, and incubated for 0, 4
and 8 h. Bright-field images were acquired using a Nikon
CoolPix digital camera adapted to an inverted bright-field
microscope with 40× magnifications. The rate of wound
healing was quantified from the images using ‘ImageJ’
(Release Alpha 4.0 3.2 and Adobe Photoshop version 6.0.)
2.5.3 NO estimation: For fluorometric NO determination,
EAhy926 cells cultured in 12-well plate and incubated
overnight, at 37°C/5% CO2. Before treatment with NO
inducers, cells were treated with 14K and SST and
incubated for 1 h. After 14K and SST treatment, NO
inducers were added to treated cells and incubated further
for 15 min. Cells were washed with PBS and then incubated
with 300 μL of DAF-FM, the cell-nonpermeable diacetate
prepared in 1× PBS containing L-arginine (1 mM) (Kojima
et al. 1998) and incubated at 37°C/5% CO2 for 15 min.
After transferring the supernatant to a 96-well plate, DAF-
2 T fluorescence was measured using a spectrofluorometer
(Cary Eclipse, EL07083326) with 495 nm excitation and
515 nm emission wavelength.
2.5.4 Tube formation: Tube formation experiments were
performed as described earlier (Madri et al. 1988). In brief,
24-well plates were coated with 150 μL matrigel per well
(10 ng/mL, BD Biosciences) and incubated at 37°C for
30 min for gelling. EAhy926 cells (1×104) in 1 mL/well
were seeded in the absence or presence of the synthetic
peptide derived from buPRL in DMEM. After 48 h of
incubation at 37°C/5%CO2 humidified atmosphere, the
centre of each well was photographed with a Nikon Coolpix
camera attached to a phase contrast microscope. Tubes
formed in each well were counted and plotted as a graph.
2.5.5 CAM assay: CAM assay was performed using fourth
or sixth day incubated white leg horn eggs (Ribatti et al.
1996). The eggs were broken and gently plated onto dishes
under sterile conditions. Disks contacting target factors
including control (1× PBS) were placed on the vascular bed
of egg yolks, and the yolks were incubated for 12 h. Images
were taken at a 20× magnification using a Nikon CoolPix
digital camera adapted to a stereo-microscope after 0, 4,
8 and 12 h of incubation. Analysis of angiogenesis was
performed by using Adobe Photoshop 7.0 and ‘Angio-
Quant’ software (Niemisto et al. 2005).
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2.5.6 Statistical analysis All experiments were performed in
triplicate (n=3) unless otherwise specified. The data are
presented as means±standard error (SE). The data were
analysed using a one-way ANOVA test as appropriate (Sigma
Stat software). P≤0.05 was considered statistically significant.
3. Results
3.1 Purification of enzyme-free buffalo
prolactin monomer
Highly pure buPRL monomer was obtained from pituitary
glands with the modified Papkoff protocol (Papkoff et al.
1965) designed with differential ethanol extractions provided
to separate both different sized forms and a single
Sephacryl S-200 chromatography gel filtration (Panchal
and Muralidhar 2008). The selected fractions after S-200
gel filtration showed more than 95% size homogeneity of
buPRL as determined by 15% SDS-PAGE and densitometry
(supplementary figure 1A and B).
The purified buPRL monomer, intact form, was con-
firmed to be free from protease, especially from acidic
protease treatment. The intact buPRL was incubated with
distillated water and 20 mM citrate/phosphate buffer
including salt (i.e. pH 3.0) at 37°C, respectively, and then
analysed by electrophoresis at frequent intervals. When the
intact buPRL was incubated in distillated water for 6 h, no
lower-sized fragments were detected in SDS-PAGE either
under non-reducing or reducing conditions (supplementary
figure 1C–F). However, when the intact buPRL was
incubated under the acidic conditions, a lower-sized form,
approximately 21 kDa, was observed in SDS-PAGE under
reducing conditions (supplementary figure 1F). The lower
form did not significantly increase in type and quantity
during the incubation time, up to 12 h.
3.2 Proteolysis buPRL
Protease-free intact buPRL was incubated with bovine
spleen CD (the ratio of substrate vs enzyme=100:1) in
acidic condition (pH 3.0) at 37°C, and then the productive
mixture was separated by a 15% gel of SDS-PAGE under
reducing conditions (figure 1A). Results indicated that the
intact buPRL was cleaved by CD at pH 3.0 and the
molecular weight of cleaved peptides were approximately
18.39 kDa (18K), 14 kDa (14K), 11.16 kDa (11K) and
7.47 kDa (7K). These sizes were identified by immunolog-
ical analysis using buPRL antiserum (figure 1B). The
mixture did not show a significant contamination of CD
(42.12 kDa and 29 kDa) (figure 1A). This enzymatic
cleavage was confirmed when in the presence of pepstatin
A (Marks et al. 1973), a known acidic protease inhibitor,
CD did not generate lower-sized peptides (figure 1C).
Analysis of the buPRL peptides by CD on 15% SDS-PAGE
indicates a time-dependent enzymatic proteolysis (figure 1D
and E). Under non-reducing conditions, the quantity and
number of the lower-sized forms increased in a time-
dependent manner (figure 1D), but under reducing conditions,
the forms showed only major three different sized bands
(figure 1E), and the band intensity of intact PRL decreased. In
6 h, the band intensity of cleaved isoforms decreased under
non-reducing conditions as well as reducing conditions. New
lowest-sized bands appeared (figure 1D and E). The acidic
hydrolysed form was detected under both conditions, and its
location changed from in between the cleaved form and
monomer under non-reducing conditions to just below
monomer under reducing conditions (figure 1D and E, L1).
The amount of cleaved isoform under non-reducing condition
decreased at 6 h incubation (figure 1D, L6).
3.3 Antiangiogenic activity of buPRL-derived peptide
fragments I: The enzymatic cleavage fragments mixture
including intact buPRL
Cell migration analysis by wound healing assay was
performed in EAhy926. The cell line expresses factor
VIII-related antigen and has the same morphological
distribution as primary endothelial cells with a doubling
time of 12 h (Edgell et al. 1983).
A dose-dependent (3.3 pg/mL to 330 μg/mL) inhibition
by buPRL peptide mixture including intact form on
migration of EAhy926 cells was observed (supplementary
figure 2A). The effect was observed over a range of dose
from 33 pg/mL to 330 pg/mL.
Hence, 33 pg/mL of the peptide mixture was used for
early stage (on the day 4) CAM assay, one of the ex vivo
methods to study angiogenesis (Ribatti et al. 1996)
(supplementary figure 2B). The blood vessel generation
reduced with the dose of the peptide mixture in a time-
dependent fashion.
3.4 Antiangiogenic activity of buPRL-derived peptide
fragments II: FPLC chromatography unbound fraction
Unbound fractions 1, 2, 3 and 4, and bound forms (fraction
5 and 6) appeared in the form of many protein peaks
(figure 2A). Fractions, each 1 mL, were collected. The flow
rate was 1 mL/min. The absorbance of these fractions was
detected at 280 nm. The bound fractions, peak no. 5 and 6,
eluted with 1 M NaCl represented buPRL monomer (data
not shown). Peak no. 2 was identified by immunoreactive
assay with buPRL antiserum (data not shown) and had
cleaved buPRL fragments (figure 2B). This fraction was
desalted by 1 K cut-off centrifugal device and lyophilized. It
was then used for antiangiogenic studies.
Thirty-three pg/mL of the FPLC unbound fraction was
incubated on the CAM vessels (figure 2C). The vessel
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length, volume and the number of vessel junction affected
by the FPLC unbound fraction was measured using
Angioquant software. The fraction significantly inhibited
the vessel growth compared with the control group.
In order to understand the possible mechanism of action,
NO production under 33 pg/mL of the FPLC unbound
fraction treatment was measured using DAF-FM assay
technique (Kojima et al. 1998). The NO production induced
by VEGF and BK in EAhy926 cell line was inhibited by the
peptides, while the peptide was unable to block Ach driven
NO production (figure 2D). The buPRL peptides were more
efficient in blocking BK-stimulated NO production than
VEGF-stimulated NO production. For the analysis, each
factor was treated with its own working concentrations to
produce NO: 10 ng/mL of VEGF, 1.24 μg/mL of BK and
1.46 μg/mL of Ach.
3.5 Antiangiogenic activity of buPRL-derived peptide
fragments III: 14K buPRL
To know which of the peptides has the antiangiogenic
effect, the peptide mixture was separated on a 15% gel by
SDS-PAGE under reducing and non-reducing conditions.
The gel slices of 18K, 17K–15K (non-reducing condition),
14K and 11K bands were checked with CAM assay. The
assay results showed that 18K and 14K under both
conditions (i.e. reduced and non-reduced) had the anti-
angiogenic action. The 11K, however, did not show activity
when not reduced (data not shown).
For the antiangiogenic study of 14K buPRL, the sized
peptides were eluted from the SDS-PAGE gel under
reducing conditions with the elution buffer (20 mM Tris-
HCl/0.1% SDS), and then desalted and lyophilized. The
prepared 14K was tested on EAhy926 cell line. The result of
the cell migration study by wound healing assay indicated
that 14K peptides were working at pg/mL range (10 to
100 pg/mL). At 14K concentration of 10 pg/mL, approxi-
mately 10% and 15% inhibition in cell migration at 24 and
48 h, respectively, was observed (figure 3A). Moreover,
14K-inhibited endothelial migrations was stimulated by
VEGF and BK (figure 3B and C).
Analysis of NO production by DAF-FM methods indicated
that 14 K (10 pg/mL) reduced NO production in EAhy926 cell
line (Data not shown), and inhibited the NO generation
induced by VEGF (30 ng/mL) and BK (1.24 ug/mL),
respectively (figure 3E). In the inhibition of NO production,
pictogram level of 14K had a considerable effect.
3.6 In silico study of buPRL
To explore a structurally and functionally important motif of
lower-sized fragments in exerting antiangiogenic action, the
Figure 1. (A) Results of SDS-PAGE analysis after colloidal Coomassie blue staining. Lane C, buPRL monomer (5 μg); Lane +, buPRL
monomer (5 μg) incubated with CD; LaneM,molecular weight marker; Lane CD, cathepsin D (7.49 μg);Msc, mature single chain (42.12 kDa);
Mlc, mature large chain (29 kDa). (B) Immunoblot of A with anti-buPRL serum indicating the cleaved fragments of buPRL by CD. (C) Effect
of pepstatin A on buPRL cleavage by CD. (D) Time course of action by CD on buPRL monomer. L1–L6 represent analysis of reaction
mixture by SDS-PAGE under non-reducing conditions after 0 and 30 min, and 1, 2, 3 and 6 h, respectively. Lane C is the control where no
enzyme was added; Lane M represents marker. (E) Same as D except that the gel was run under the reducing conditions.
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structure of the lower-sized fragment was modelled. The
structure of intact buPRL was built with the template based on
human PRL, 1n9dA (Keeler et al. 2003), by SWISS-MODEL
homology modelling programme (Schwede et al. 2003;
Arnold et al. 2006) (figure 4A). ABY67078 (figure 4D) was
used for the prediction. The predicted structure had 74.242%
sequence identity to the template and 3.31e−87 expected
value (E-value). N-terminal started from blue loop structure
and C-terminal ended with the red loop structure
(figure 4A).
With the concept that only the N-terminal 16K peptide
in human PRL has the antiangiogenic effect (Ferrara et
al. 1991; Clapp et al. 1993; Khurana et al. 1999b), the
tertiary structure of 14K (Thr1-Met132) buPRL was
predicted from N-terminal amino acid sequence
(figure 4B). The 14K buPRL structure (71.429% sequence
identity and 1.60e−60 E-value) consisted of two and a half
α-helixes.
In order to narrow down further in the motif in N-
terminal fragment which has an antiangiogenic effect,
Figure 2. (A) FPLC profile of peptide mixture obtained after CD cleavage of buPRL. (B) SDS-PAGE analysis under reducing
conditions of fractions 1, 2 and 3 of A. (C) CAM assay analysis of the pooled FPLC unbound fractions (33 pg/mL) using ‘AngioQuant’.
(D) Effects of the varying concentration of FPLC unbound fractions (0, 33 and 333 pg/mL) on BK, VEGF or Ach-induced NO production
in EAhy926 cell line. Values are means±SEM. *Significantly different from the respective positive control at P<0.05. (E) A schematic of
the role of NO in angiogenesis.
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alignments between ABY67078 and some known anti-
angiogenic factors like human somatostatin (hSST)
(Florio et al. 2003) were performed with the ‘protein
tools’ in Biology WorkBench 3.2. The alignment with
hSST showed 35.71% sequence identity among the 14
residues shown in figure 4. This area, Ala45-Gln46-Gly47-
Lys48-Gly49-Phe50-Ile51-Thr52-Met53-Ala54-Leu55-
Asn56-Ser57-Cys58 (figure 4D), was located in the initial
second loop, after the first α-helix (figure 4). This area in the
predicted 14K structure was placed at the open environment
(figure 4B), but not in intact PRL (figure 4A). This SST-
matching sequence was commercially synthesized to study its
antiangiogenic action.
3.7 Antiangiogenic activity of buPRL derived peptide
fragments III: Comparison to SST, antiangiogenic peptide
For comparative study between buPRL fragment and hSST
in the antiangiogenic action, NO production analysis
(figure 3E) and CAM assay with both factors were
performed (figure 5). The inhibitory effect of cell migration
by SST appeared in the concentration range of 86 ng/mL to
Figure 3. Results of wound healing assay (cell migration assay) in EAhy926 cell line. (A) Effect of 14K fragments at different doses
measured at 4 and 8 h. (B) Effect of 14K peptides (10 pg/mL) combined with VEGF (30 pg/mL). (C) Effect of 14K peptides combined with
BK (1.24 μg/mL). (D) Dose-dependent effect of SST on NO production in EAhy926 cell line. (E) Inhibition of BK- or VEGF-stimulated NO
production by 14K (10 pg/mL) and SST (164 ng/mL). Values are means±SEM. *Significantly different from controls at P<0.05.
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1.64 μg/mL. (figure 3D). 10 pg/mL (approximately 0.7 pM)
of the 14K and 164 ng/mL (0.1 μM) of SST showed
inhibitory effect on NO production induced by BK and
VEGF (figure 3D). The inhibition of growth of vessels was
also investigated in both cases. In the case of 14K eluted
from the gel, even a part of the main blood vessel
disappeared (figure 5A and Bi). Picogram levels of the
14K showed stronger activity than nanogram levels of SST
(figures 3E, and 5A and B).
3.8 Antiangiogenic activity of buPRL-derived peptide
fragments IV: By synthetic peptide derived from buPRL
For structure–function comparative study between buPRL
and hSST on the antiangiogenic function, the synthetic
peptide, Ala-Gly-Lys-Gly-Phe-Ile-Thr-Met-Ala-Leu-Asn-
Ser-Cys (13 mer) (lacking Gln in the 2nd position),
derived from the second loop of buPRL aligned with
human SST, was used for cell migration assay, CAM
assay and tube formation (figure 5B–E). The EAhy926
cells migration was inhibited at 1 pg/mL of the synthesized
peptide derived from buPRL, but this phenomenon did not
exhibit dose dependence (figure 5C). The vessel develop-
ment in chorioallantoic membrane reduced and disap-
peared at even 1 pg/mL (approximately 0.7 pM) of the
buPRL-derived peptide treatment (figure 5D). The anti-
angiogenic function of synthesized peptide was confirmed
using tube formation assay. Tube formation by endothelial
cells (vessel tunnel) was blocked at 1 pg/mL of the
synthesized peptide treatment (figure 5E).
Figure 4. Tertiary structures of buPRL built by SWISS MODEL. (A) Tight four α-helices and loops of intact buPRL (GeneBank
accession number: ABY61078) in SWISS-Pdb viewer 4.0. (B) Buffalo N-terminal 14K peptide (Thr1-Met132). (C) Human C-terminal
16K (Ala54-Cyc199). (D) Results of alignment of the amino acid sequence of bu PRL with that of hSST.
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4. Discussion
When incubated with acidic buffer, the buPRL monomer
generated a 21K fragment but there was no time-dependent
increase in the concentration of the 21K fragment, indicat-
ing that this fragment arose as a result of hydrolysis of a
disulfide loop either at the N-terminal or at the C-terminal
and not due to nicking of peptide bond (supplementary
figure 1E and F). This proves that the purified intact buPRL
was protease free, especially acid protease, and therefore
would be an ideal candidate for use in proteolysis studies. In
the present study, the cleaved isoform with a nick in the
large disulphide loop (Mittra 1980b) seemed to produce
18K and 7K or 14K and 7K by reduction. Moreover, the
cleavage action of the endosomal acidic enzyme, CD, may
have a recognition pattern at the cleavage site in the amino
acid sequence of buPRL.
The sizes of buPRL fragments obtained by CD are
different from the sizes of cleaved fragments of PRL from
other species: rat pituitary (16K and 8K) (Mittra 1980a, b),
mouse pituitary (16K and 8K) (Sinha and Gilligan 1984),
and human pituitary (17K, 16.5K, 15K, 11K, 8K and 5K)
(Piwinica et al. 2006) PRL (figure 6A). These different
patterns of cleavage could be due to micro-variation in the
primary structure among species. Comparing the cleaved
sequences between human and rat PRLs, Tyr147-Pro148-
Val149-Trp150-Ser151 of human and Tyr145-Leu146-
Val147-Trp148-Ser149 of rat are homologous (Piwinica
et al. 2006) (figure 6B). The presence of Pro148 and
Leu132 controlled the cleavage pattern in hPRL (Piwinica
Figure 5. Results of CAM assay of 14 K and SST. (A) Antiangiogenic effect in time-dependent manner. (B) The estimation of vessel
length, size and junction number. The Antiangiogenic activity by the synthesized peptide derived from buPRL. (C) Cell migration by
wound healing assay. (D) CAM assay. (E) Tube formation assay. Values are means±SEM. *Significantly different from controls P<0.05.
**P<0.01. Appropriate actual photographs are indicated as Bi and Ci.
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et al. 2006). Pro148 prevented high cleavage efficiency at
147–148 and 150–151 sites, while Leu132 produced the
additional cleavage at 132–133 sites (Piwinica et al. 2006).
Buffalo PRL sequence has the same sequence at 147–151
sites as in hPRL, but not at residue 132 site (figure 6B).
The Pro148 in buPRL also seems to link to a specific
cleavage pattern. Hence, 18K and 14K of buPRL were
considered homologous to 17K and 15K of hPRL,
respectively. We could not detect a fragment similar to
the 16.5K fragment of hPRL.
Angiogenesis, the process of developing new blood
vessels from preexisting vessels, is crucial to reproduction,
growth and wound healing (Folkman and Shing 1992). In
the last two decades, numerous studies reported novel
angiogenic regulators (Iyer and Acharya 2002). Among
the angiogenic regulators, PRL fragment is one of the very
paradoxical molecules. Its intact form has pro-angiogenic
action (Struman et al. 1999), inducing cell proliferation and
motility, and relates to breast carcinogenesis (Clevenger
et al. 2003). The PRL fragments as well as intact PRL were
are also known to be secreted from vascular endothelial
cells (Ochoa et al. 2001). The antiangiogenic and anti-
mitogenic effects of peptide fragments were observed in
BBBE and HUVE cells, respectively, by incubating them
with PRL antibody, which suggested the possibility that
they act as autocrine regulators of angiogenesis, (Clapp
et al. 1998; Corbacho et al. 2000).
In the present study, the antiangiogenic activity of
buPRL-derived peptides was demonstrated in vitro and ex
vivo. Endothelial cell migration is fundamental to angio-
genesis (Lamalice et al. 2007), because endothelial cells,
derived from mesodermal cells, form capillary blood and
lymphatic vessels (Venes and Thomas 2001). Earlier reports
found antiangiogenic activity of r16K (Ferrara et al. 1991)
and recombinant h16K (Clapp et al. 1993; D’Angelo et al.
1999) in nanomalar concentrations. The present study
demonstrates that buPRL-derived peptides have an anti-
angiogenic activity in picomolar concentration. Even the
cleaved fragments mixed with intact buPRL, considered a
pro-angiogenic factor (Struman et al. 1999), are effective at
Figure 6. CD and thrombin cleavage site in the primary sequences of rat, human, buffalo and cattle PRLs. (A) In human PRL three N-
termini by CD and C-terminus by thrombin (figure from Piwnica, et al. 2004). (B) CD cleavage sites in rat, human, buffalo and cattle
PRLs. (C) The SST aligned sequences of buPRL and buGH are partially or completely involved in the sequence of N-terminus fragment
known as antiangiogenic factor. Triple * in hSST is the specific binding site to SSTRs. The square window indicates the considered
sequence has an antiangiogenic action. Arrows indicate the cleavage sites. (D) hSST in SWISS-Pdb viewer 4.0. Blue arrows and alphabets
represent SST receptor binding sites. (E) The synthetic peptide derived from buPRL..Molecular size and pI of each peptide were gained
from ExPASy Proteomics tools.
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the lower concentration level (supplementary figure 2). The
results of our study prove that buPRL peptides cleaved by
CD have the antiangiogenic action, and these negative
factors for angiogenesis should be N-terminal peptides.
These peptides inhibited NO production and hence NO-
mediated angiogenesis stimulated by VEGF or BK.
NO, produced by NO synthase (NOS), is a second
messenger in the regulation of physiological and patho-
physiological process in the cardiovascular, nervous and
immune systems (Moncada and Higgs 1993; Nathan and
Xie 1994). NO is involved in cell migration and cell
protection (Lee et al. 2005; Kolluru et al. 2007). NO-
mediated pathway is a well known signalling mechanism of
angiogenesis, vasopermeability and vasorelaxation in rela-
tion to VEGF (Ferreira and Henzel 1989; Ishikawa et al.
1989), BK (Regoli and Barabe 1980; Ferreira et al. 1992)
and Ach (Palmer et al. 1989) actions (figure 2E). Gonzalez
et al. (2004) reported that human and rat 16K PRL
fragments inhibited NOS activation induced not only by
VEGF and BK but also by Ach, in endothelial cells. Buffalo
PRL fragments seem not to be correlated to the pathway
stimulated by Ach in EAhy926 (figure 2D). Moreover, the
buPRL peptides were more effective in inhibiting the BK-
mediated NO mechanism than that by VEGF (figure 2D). It
is not known, however, how this peptide blocks the NO
pathway. We envisage two possible mechanisms. One is that
the peptides act as receptor antagonists of angiogenic factors,
and the other is that the peptides induce another pathway to
inhibit NO production driven by these angiogenic factors.
Besides, the role of individual amino acid residues in the
antiangiogenic action is not yet clear.
Generally, the conformation of the cleaved fragment is
either new and unstable or native-like which is less stable
than that of the original (Creighton 1993). No experimental
details are available on the conformation of the cleaved
fragment. Nevertheless, a significant difference in the N-
terminal 14K PRL structure from the intact PRL was that
the loop between the first and the second α-helices were
loosened and more opened to the environment. In the intact
form, the loop was close to the fourth α-helix (figure 4A).
The disulfide bond between the loop and the fourth α-helix,
between Cys58 and Cys174, in the centre of the loop might
be giving more compact configuration.
Somatostatin, a small peptide (14 amino acids)
secreted from hypothalamus, is a negative regulator of
growth hormone (GH) release (Norman 1997). Widely
distributed throughout the body, SST binds to five
different subtypes of its cognate receptors (SSTR1-5),
one of them being a G-protein-coupled receptor present on
the cell membrane (Patel et al. 1990; Lahlou et al. 2004).
While the five SSTRs bind the natural peptide, SSTR2,
SSTR3, and SSTR5 can bind its synthetic analogues
(Lahlou et al. 2004). SST and its analogues inhibit
angiogenesis and also the production and secretion of
angiogenic factors including VEGF (Barrie et al. 1993). It
was reported that SST blocked Kaposi sarcoma (KS) cells
(KS-Imm), isolated from a kidney-transplanted, immuno-
suppressed patient and also highly angiogenic, xenografts
into nude (nu/nu) mice through angiostasis (Albini et al.
1999). SST also induced cell death of human somatotrph
tumor cells (SSTR2) (Ferrante et al. 2006). In the study
with vascular endothelial cell (dominated by SSTR3;
Reisine and Bell 1995), SST inhibited cell proliferation
through blocking of both endothelial NOS (eNOS) and
MAPK activations. SST is a powerful anti-tumour angio-
static agent. The results of the present work (figures 3, 6A
and 6B) confirm that SST and 14K buPRL are significant
antiangiogenic factors, and 14K is more effective than SST
in the antiangiogenesis assays. The antiangiogenesis
brought about by buPRL fragment seems to be related to
the inhibition of vasopermeability of endothelial cells
(figure 2D).
Small ligands tend to bind, relatively speaking, the
interior of globular proteins, while linear ligands tend to
bind in clefts on the surface of proteins (Creighton 1993).
The small and linear structure of the synthesized peptide
(figure 6E) enables it to bind to both the interior of putative
receptors and to the clefts on the surface of receptors. The
synthetic peptide, Ala45-Gly47-Lys48-Gly49-Phe50-Ile51-
Thr52-Met53-Ala54-Leu55-Asn56-Ser57-Cys58, also
showed more active than SST in the antiangiogenic action.
This SST-matching sequence peptide had a structure (linear)
different from SST, which had α-helix structure (figure 6D).
This active motif for antiangiogenesis is not involved in
binding to the PRLR sites, especially the second half of loop
1 (His59, Pro66 and Lys69) of site 1 (Goffin et al. 1992).
This result also demonstrates that Ala45 to Met53 can be the
active sites for angiostatic function. The C-terminal 16K
peptide (54–199 residues) of hPRL does not appear to have
the function of antiangiogenesis (Khurana et al. 1999b)
(figure 6A). However, in the C-terminal 16K fragment of
hPRL, the fourth helix is still close to the partial second
loop, which becomes exposed to environment in the N-
terminal 16K fragment of hPRL (figure 4B and C). Because
of this, the C-terminal 16K fragment of hPRL may not have
antiangiogenic action.
Three residues, Phe7-Trp8-Lys9, in SST sequence
appear to have the crucial role in binding with high
affinity to all SST receptors, SSTR1 to SSTR5 (Poitout et
al. 2001). However, in the synthetic sequence derived from
buPRL, Ala1-Gln2-Gly3-Lys4-Gly5-Phe6-Ile7-Thr8-
Met9-Ala10-Leu11-Asn12-Ser13-Cys14, ‘Ile7-Thr8-Met9’
is found instead of ‘Phe7-Trp8-Lys9’. In the SST-matching
sequence of hPRL, ‘Ile51-Thr52-Lys53’ replaces the SST
tri-peptide sequence (‘Phe7-Trp8-Lys9’) positions
(figure 6C). This leads to the question of whether buPRL
fragments bind to SSTR3 or not, and if the fragments
bind to SSTR3, which residues in the sequence of the
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fragments bind to the receptor and mediate the antiangio-
genic action. In the PRL fragments- and SST-mediated
inhibition of the angiogenesis, there are similar mecha-
nistic patterns. Both factors blocked VEGF-induced cell
proliferation, which is known to be through the MAPK
pathway in vascular endothelial cells (D’Angelo et al.
1999).
The hPRL and hGH tilted peptides (14-amino-acid
sequence) consisting of 9 hydrophobic amino acids induce
endothelial cell apoptosis and inhibit endothelial cell
proliferation and capillary formation (Nguyen et al. 2006).
The tilted peptide has been known to destabilize membrane
and lipid core and is characterized by an asymmetric
distribution of hydrophobic residues along the axis when
helical. However, the synthetic tilted peptides derived from
hPRL and hGH show 4 times and 32 times less activity,
respectively, than the 16K hPRL in vitro (Nguyen et al.
2006). The synthetic peptide related to buPRL represents
differences in structure and functional sensitivity from
those of the tilted peptides. This peptide has similar
sensitivity with 14K buPRL in the inhibition of angio-
genesis in vitro and ex vivo. Although the peptide includes
9 hydrophobic amino acids, it does not form a helix
(figure 6E). These differences imply that the synthetic
peptide related to buPRL has a receptor-binding mediated
antiangiogenic function, rather than protein-membrane-
interaction-mediated function.
The present study suggests that buPRL gives upon
cathepsin digestion a 16K-like fragment, but of 14K size
and more cleaved fragments in buPRL, which have an
antiangiogenic action. The antiangiogenic action of the
fragments is, at least, related to the initial part of the
sequence of the second loop between first and second α-
helices. Furthermore, the synthetic peptide (derived by
hSST matching area of buPRL) can be a potential anticancer
therapeutic agent as well as for treatment of vascular,
rheumatoid and other diseases whose etiology necessarily
involves angiogenesis (Folkman 1995). Confirming the
relevance of this idea requires demonstrating whether the
buPRL fragments have N-terminal structure, and whether
there are other sequences between Thr1-Tyr44 having
antiangiogenic action. Further work is required to explore
whether SSTR3 is the specific receptor for 14K and other
cleaved peptides, and if not, what is the specific receptor to
the peptides, and what sequence part plays a crucial role in
this antiangiogenic action?
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